narsoplimab | Narsoplimab (OMS721; MASP-2 Inhibitor, Lectin Pathway) -

Keyword	CPC	PCC	Volume	Score	Length of keyword
narsoplimab	1.93	0.6	7986	79	11

Keyword	CPC	PCC	Volume	Score
narsoplimab	1.35	0.1	3207	42

Search Results related to narsoplimab on Search Engine

Narsoplimab (OMS721; MASP-2 Inhibitor, Lectin Pathway) - Omeros
omeros.com

https://www.omeros.com/narsoplimab/

WEBNarsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. The lectin pathway is one of the principal pathways of complement and is activated primarily by tissue damage and microbial infection.

DA: 70 PA: 48 MOZ Rank: 24

Narsoplimab, a Mannan-Binding Lectin-Associated Serine …
ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.21.02389

WEBApr 19, 2022 · Narsoplimab is a fully human monoclonal antibody that binds to and inhibits mannan-binding lectin-associated serine protease-2, the effector enzyme of the lectin pathway and an activator of the coagulation cascade.

DA: 56 PA: 85 MOZ Rank: 93

Narsoplimab: What is it and is it FDA approved? - Drugs.com
drugs.com

https://www.drugs.com/history/narsoplimab.html

WEBNarsoplimab is an investigational human monoclonal antibody in development for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) is a significant and often lethal complication of stem cell transplantation.

DA: 97 PA: 8 MOZ Rank: 59

Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609886/

WEBAug 13, 2020 · Narsoplimab is a human monoclonal antibody against mannan-associated lectin-binding serine protease−2 (MASP-2). Now in a phase 3 study, narsoplimab was evaluated in a staged phase 2 study assessing safety and effectiveness in high-risk patients with IgA nephropathy (IgAN).

DA: 52 PA: 4 MOZ Rank: 7

IgA nephropathy | Nature Reviews Disease Primers
nature.com

https://www.nature.com/articles/s41572-023-00476-9

WEBNov 30, 2023 · Narsoplimab (OMS721) is a fully human IgG4 monoclonal antibody that inhibits MBL-associated serine protease 2 (MASP2), the key effector enzyme of the lectin pathway.

DA: 3 PA: 1 MOZ Rank: 49

Successful use of narsoplimab to treat allogeneic transplant
nature.com

https://www.nature.com/articles/s41409-024-02263-w

WEBMar 11, 2024 · Narsoplimab (Omeros Corporation, Seattle, WA) is a novel, fully human immunoglobulin G4 monoclonal antibody that inhibits mannan-binding lectin-associated serine protease-2 (MASP2), the effector...

DA: 81 PA: 29 MOZ Rank: 6

Clinical Safety and Efficacy of Narsoplimab in Pediatric and Adult
ashpublications.org

https://ashpublications.org/blood/article/142/Supplement%201/3543/500867/Clinical-Safety-and-Efficacy-of-Narsoplimab-in

WEBNov 28, 2023 · Narsoplimab (OMS721) is a fully human IgG4 antibody that binds MASP-2, the effector enzyme of the lectin pathway of the complement system. A recent pivotal trial demonstrated the safety and efficacy of narsoplimab in patients with TA-TMA.

DA: 72 PA: 96 MOZ Rank: 39

Narsoplimab, a Mannan-Binding Lectin-Associated Serine …
ascopubs.org

https://ascopubs.org/doi/abs/10.1200/JCO.21.02389

WEBApr 19, 2022 · Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangiopathy | Journal of Clinical Oncology. Open access. ORIGINAL REPORTS. April 19, 2022.

DA: 47 PA: 41 MOZ Rank: 16

Narsoplimab, a Mannan-Binding Lectin-Associated Serine
nih.gov

https://pubmed.ncbi.nlm.nih.gov/35439028/

WEBAug 1, 2022 · Narsoplimab (OMS721), an inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2), was evaluated for safety and efficacy in adults with HSCT-TMA. Methods: In this single-arm open-label pivotal trial ( NCT02222545 ), patients received intravenous narsoplimab once weekly for 4-8 weeks.

DA: 77 PA: 95 MOZ Rank: 4

Omeros Reports Final Efficacy and Safety Data from the Narsoplimab
omeros.com

https://investor.omeros.com/news-releases/news-release-details/omeros-reports-final-efficacy-and-safety-data-narsoplimab

WEBNarsoplimab, an inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway and activator of the coagulation cascade, is being studied for the treatment of HSCT-TMA patients at high risk for poor outcomes.

DA: 16 PA: 75 MOZ Rank: 38